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need for political unity, substantial financial investments, and adaptability when 
faced with obstacles and suboptimal results.
PHP187
THe FuTure oF educaTion in HTa and HealTH economics
Carroll C., Beecroft C., Miller L.
The University of Sheffield, Sheffield, UK
Objectives: An increasing range of online education is available to those working 
in the field of pharmaco-economics and Health Technology Assessment (HTA). The 
aim of this study was to explore the market for free online education in HTA and to 
assess the practicalities of delivering a free, interactive short-course. MethOds: 
We delivered a 5-week online course at the end of 2013 following the princi-
ples of the Massive Open Online Course (MOOC) approach: the HTA MOOC. The 
programme covered the basics of HTA: What it is; how new technologies are 
identified; how they are evaluated; the principal means of assessing clinical and 
cost-effectiveness; and how HTA is used within different health systems to inform 
reimbursement decisions. The course was provided through the Coursesites, a free, 
open-access, education platform. Materials were adapted from an existing online 
MSc programme. Descriptive statistics of participants were recorded and a survey 
conducted of participants’ experiences. Results: 2039 individuals registered for 
the HTA MOOC, of which 1508 completed a voluntary survey giving basic socio-
demographic data about themselves. Participants were from Europe (55%), Asia 
(16%) and North America (13%) and accessed the MOOC to gain knowledge about 
the subject (78%), and specifically for career development (56%). 531/2039 (26%) 
of those registered in Week 1 completed the MOOC (i.e. submitted all required 
weekly assessments by the end of Week 5), compared to an average of 5-6% for 
MOOCs generally [THES 2013]. Students reported the principal strength of the 
programme to be the quality and usefulness of the learning materials, and the 
principal issue to be time required (workload was considered by some to exceed 
the 4-5 hours/week intended). cOnclusiOns: The MOOC approach offers scope 
for delivering flexible, effective and accessible education to small or large inter-
national cohorts of professionals, patients and providers working within HTA and 
pharmaco-economics.
PHP190
PHarmacoeconomic educaTion in Brazilian scHools oF PHarmacy
Freitas G.1, Balbinotto G.2
1UFRGS, Porto Alegre, Brazil, 2Universidade Federal Do Rio Grande Do Sul, PORTO ALEGRE, Brazil
Objectives: The objective of this study was to survey the pharmacy schools in 
Brazil to determine the extent of education in pharmacoeconomics offered during 
the school year 2012-2013. MethOds: A questionnaire based on previous studies 
was developed. This was emailed to 55 pharmacy schools in Brazil during October 
and December 2013. The schools were selected from the Ministry of Education 
website. Public and private University schools (only those that have high concepts 
in the National Examination Performance of Students) were included. In addition, 
a search was made in the database directories of research groups from National 
Council for Scientific and Technological Development (CNPq). Results: Of the 55 
questionnaires sent, 16 were returned (29%). Only two schools do not address the 
education of pharmacoeconomics in any moment. Most of schools address some 
concepts in different subjects (8 hours). Five schools have formal courses that 
teach only pharmacoeconomics and health technology assessment (over 30 hours). 
All agree that the education of pharmacoeconomics is important and ten schools 
believe that very few hours are devoted to the teaching pharmacoeconomics at 
his university. In search of directories of research groups 23 groups that develop 
research in the area of pharmacoeconomics in Brazil were found. cOnclusiOns: 
There is a large deficit in the availability of courses pharmacoeconomics in Brazil 
at both the undergraduate and graduate. There is a great opportunity for expe-
rienced individuals to fill this gap. Provide an education in pharmacoeconomics 
for pharmacy students is especially important in the context of evidence-based 
decisions and when health issues and allocation of scarce resources is a priority 
for Brazil.
PHP191
aPPlicaTion oF a ‘nice PosT-Hoc B/s analysis’ To THe nice aPPraisal 
Process
Macaulay R.
HERON Commercialization, London, UK
Objectives: Post-hoc subgroup analyses are still used in clinical trials of medi-
cal technologies to identify patient populations in whom greatest benefits can 
be achieved, despite this being derided as an analytical approach. Indeed, using 
such an approach, aspirin has been shown to be ineffective versus placebo in 
acute myocardial infarction patients born under the star signs of Libra and Gemini 
(ISIS-2, 1988, Lancet) and endarterectomy is only efficacious in treating sympto-
matic stenosis patients born on a Monday, Wednesday, or Friday (ECST group, 1998, 
Lancet). This research aimed to determine what effect the name of a drug has 
on the National Institute of Health and Care Excellence (NICE) appraisal process 
by applying a post-hoc analysis that compares the rates of acceptance by the 
first letter of the drug or technology name using a Chi-squared test. MethOds: 
All final appraisal determinations resulting from Single Technology Appraisal 
(STA) or Multiple Technology Appraisal (MTA) processes were identified up 
to April 2014 from which the first letter of the generic name and the decision 
were extracted. Results: 481 appraisals were identified, 371 (77%) of which 
were approved (defined as ‘recommended’ or ‘optimised’), spanning all letters 
of the alphabet except J, K, W, X, and Y. The lowest approval rates by letter were 
for B (64%, 14/22) and S (69%, 18/26). Drugs beginning with a B or S were sig-
nificantly less likely to be approved than drugs beginning with any other letter 
(p= 0.0072). cOnclusiOns: Based on this ‘NICE post-hoc B/S analysis,’ manufac-
turers should consider lobbying the World Health Organization to give their new 
pharmaceuticals International Nonproprietary Names beginning with ‘B’ or ‘S’ 
to optimise success rates in the NICE appraisal process. Alternatively, regulators 
and HTA bodies should continue to view efficacy claims on the basis of post-hoc 
sub-group analyses with great scepticism.
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imPacT oF sTory Books on PromoTing knowledge and BeHavior oF 
4TH sTage elemenTary sTudenTs aBouT raTional use oF medicines in 
kermansHaH Provine oF iran 2008
Mohammadhosseini N.
National Committee on Rational Drug Use, Tehran, Iran
Objectives: Evaluation of the impact of children stories on promotion 
of the knowledge and behavior of 4th stage elementary students about 
rational use of medicines in the Kermanshah elementary schools. MethOds: 
64 elementary schools were selected in Kermanshah province of Iran. The 
schools were categorized into 3 groups (rich, medium and poor level) based on 
their students’ economic level. Both boys and girls were involved. Two checklists 
were designed in order to evaluate students’ knowledge and behavior before 
and after the intervention. A story book which was published by National 
Committee of Rational Drug Use (RUD) conveyed to the students as the inter-
vention. Results:  The correlation between pre and post intervention and the 
schools economic levels and the gender of students were obtained. The knowl-
edge change rates were 21.83%, 22.28% and 17.40% for rich, medium and poor 
schools respectively. The change rate for girls was greater in comparison to 
that of boys. cOnclusiOns: It is concluded that children stories as an educa-
tional intervention causes valuable positive changes on students’ knowledge 
and behavior regarding hygiene and medicine. Implementing such interven-
tions among children, result in promoting rational use of medicines in future 
of the society.
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clinical Trials in France: an underexPloiTed oPPorTuniTy
Mahi L., Mahi I.
Axelys Sante Affaires Medicales et Recherche Clinique, Paris, France
Objectives: Despite high-performance infrastructures and recognized 
expertise, Clinical trials (CT) are declining in France. Health Professionals 
deplore the burdens of the French administration that leads to a real concern 
regarding the international scientific competition. In addition patients are reluc-
tant to participate in CT especially after the benfluorex scandale. MethOds: One 
of the witnesses of the competitiveness of France in CT is the activities among 
Clinical Investigation Centers (CIC). These are plateforms fully dedicated to clini-
cal and scientific research acting as an interface between INSERM units (Public 
National Institut of Scientific Research) and CHU (University Hospital). Results: 
There are 54 CIC in France. They have been created between 1992 and 2009. CICs 
are located in university hospitals (CHU) dessiminated in the most important 
regions of the country. The specific needs of CHU and researchers have led to 
implement several types of CICs: multi-topics (24 CIC-P), Clinical Epidemiology 
(9 CIC-EC), integrated in biotherapy (11 CIC-BT) and technological innovations (8 
CIC-IT). During the last quadrennium, CIC-P supervised about 1000 protocols, of 
which 2/3 were therapeutic and 1/3 on physiopathology. 25% of protocols con-
ducted in CIC-P were translational in collaboration with INSERM units, 20% were 
for rare diseases, 35% were funded by industry and 36% by the PHRC (Academic 
funding). The AP-HP (Academic Hospitals of Paris Area) is the major sponsor in 
France and one of the first in Europe, with 500 clinical trials enrolling more than 
17,000 patients in 2010. Despite this development, the number of CT submis-
sions to ANSM (French Regulatory Agency) decreased from 1,000 in 2008 to 895 in 
2012. ANSM approuved 705 protocols in 2012 versus 790 in 2008. cOnclusiOns: 
Despite appropriate structures and willingness to encourage scientific produc-
tion, clinical trails remain underexploited due to different causes which need to 
be deeply evaluated.
HealTH care use & Policy sTudies – Health Technology assessment  
Programs
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will value Based assessmenT (vBa) revoluTionise THe nice 
assessmenT?
Heemstra L.1, Purchase J.L.2, Van Engen A.1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Reading, UK
Objectives: In March, the National Institute for Health and Care Excellence (NICE) 
revealed their plans to implement Value Based Assessment (VBA) in their Technology 
Appraisal process: VBA will replace NICE’s end-of-life criteria. Instead wider soci-
etal impact (WSI) and burden of illness (BOI) will be systematically included in the 
assessment through absolute and proportional Quality Adjusted Life Year (QALY) 
shortfall. However, it is unclear whether these elements will impact NICE’s recom-
mendations. MethOds: The BOI and WSI for the 26 examples provided by NICE 
was compared with an average displaced treatment in the NHS. Assuming that both 
elements were weighted equally, an average QALY shortfall rating was calculated. 
This was then transformed into a hypothetical willingness to pay (WTP) threshold 
ranging from £20,000 for the drug with the lowest rating to £50,000 per QALY for 
the drug with the highest rating. The hypothetical WTP was compared with the 
most plausible ICER and recommendation from NICE. Results: Multiple Sclerosis, 
rheumatoid and psoriatic arthritis, as well as oncology indications were associated 
with a high BOI/WSI. Six of the 26 examples had higher most plausible ICERs than 
the estimated threshold. Two of these six were still recommended using end-of-
life criteria (metastatic melanoma and mCRPC), whereas the remainder were not 
recommended by NICE. Three of the 26 examples had ICERs below the estimated 
WTP threshold but higher than £30,000, and were still recommended. All of these 
recommendations mentioned additional value elements such as innovation, end-of-
